Diurnal

Diurnal, founded in 2004, is a UK-based global specialty pharmaceutical company dedicated to developing high-quality products for the lifelong treatment of chronic endocrine diseases. The company focuses on addressing significant unmet clinical and patient needs in hormone replacement, initially developing and marketing products for rare orphan diseases such as congenital adrenal hyperplasia (CAH) and adrenal insufficiency (AI). Through its extensive knowledge, experience, and perseverance, Diurnal has created specialized and valuable product opportunities to improve the treatment of hypogonadism, hypothyroidism, and other endocrine disorders, with the primary goal of enhancing patient outcomes and quality of life.